FDA
approval
· 2018-10-31
FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)
Summary
FDA approved a supplemental application for Lannett Company's generic buprenorphine and naloxone product, enabling marketing of a generic formulation for opioid…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)